Mohamed S. Dabour

Tanda, GH, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?

Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?

Journal: Breast cancer research and treatment

Published: March 22, 2026

Psychosocial stress exacerbates doxorubicin-induced cardiotoxicity in adult C57BL/6N mice.

Psychosocial stress exacerbates doxorubicin-induced cardiotoxicity in adult C57BL/6N mice.

Journal: Research square

Published: January 16, 2026

Integrated Omics Approach to Delineate the Mechanisms of Doxorubicin-Induced Cardiotoxicity.

Integrated Omics Approach to Delineate the Mechanisms of Doxorubicin-Induced Cardiotoxicity.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 02, 2026

Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline-Induced Cardiotoxicity Using an Integrated PK/PD Model.

Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline-Induced Cardiotoxicity Using an Integrated PK/PD Model.

Journal: Clinical and translational science

Published: December 28, 2025

Integrated Omics Approach to Delineate the Mechanisms of Doxorubicin-Induced Cardiotoxicity.

Integrated Omics Approach to Delineate the Mechanisms of Doxorubicin-Induced Cardiotoxicity.

Journal: bioRxiv : the preprint server for biology

Published: July 16, 2025

Substrain-Dependent Differences in Doxorubicin-Induced Cardiotoxicity in Adult C57BL/6 Mice.

Substrain-Dependent Differences in Doxorubicin-Induced Cardiotoxicity in Adult C57BL/6 Mice.

Journal: Cardiovascular toxicology

Published: July 01, 2025

SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction: Expanding the Evidence.

SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction: Expanding the Evidence.

Journal: JACC. CardioOncology

Published: January 13, 2025

Long-Term Care of Childhood Cancer Survivors at Risk for Cardiac Late Effects.

Long-Term Care of Childhood Cancer Survivors at Risk for Cardiac Late Effects.

Journal: JACC. CardioOncology

Published: October 30, 2024

Canagliflozin differentially modulates carfilzomib-induced endoplasmic reticulum stress in multiple myeloma and endothelial cells.

Canagliflozin differentially modulates carfilzomib-induced endoplasmic reticulum stress in multiple myeloma and endothelial cells.

Journal: Archives of toxicology

Published: September 12, 2024

Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy.

Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy.

Journal: Antioxidants (Basel, Switzerland)

Published: April 24, 2024

Losmapimod ameliorates doxorubicin-induced cardiotoxicity through attenuating senescence and inflammatory pathways.

Losmapimod ameliorates doxorubicin-induced cardiotoxicity through attenuating senescence and inflammatory pathways.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 28, 2024

The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review.

The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review.

Journal: JACC. CardioOncology

Published: October 10, 2023

Showing 1-12 of 14

Last Updated: 09/26/2026